Open Access Research Article

CYP4V2 Fatty Acid Omega Hydroxylase, A Druggable Target for The Treatment of Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease (NAFLD)

Nicholas Osborne1, Charles Leahy1, Yoon Kwang Lee1 and James P Hardwick1*

1Department of Integrative Medical Sciences, Northeast Ohio Medical Universities, USA

Corresponding Author

Received Date:September 13, 2021;  Published Date: October 26,2021


Fatty acids are essential in maintaining cellular homeostasis by providing lipids for energy production, cell membrane integrity, protein modification, and the structural demands of proliferating cells. Fatty acids and their derivatives are critical bioactive signaling molecules that influence many cellular processes, including metabolism, cell survival, proliferation, migration, angiogenesis, and cell barrier function. The CYP4 Omega hydroxylase gene family hydroxylate various short, medium, long, and very-long-chain saturated, unsaturated and polyunsaturated fatty acids. Selective members of the CYP4 family metabolize vitamins and biochemicals with long alkyl side chains and bioactive prostaglandins, leukotrienes, and arachidonic acids. It is uncertain of the physiological role of different members of the CYP4 omega hydroxylase gene family in the metabolic control of physiological and pathological processes in the liver. CYP4V2 is a unique member of the CYP4 family. CYP4V2 inactivation in retinal pigment epithelial cells leads to cholesterol accumulation and Bietti’s Crystalline Dystrophy (BCD) pathogenesis. In this commentary, we provide evidence of the role CYP4V2 has in metabolic syndrome and non-alcoholic fatty liver disease progression. This is accomplished by identifying its role in BCD, its control of cholesterol synthesis and lipid droplet formation in c. elegans, and the putative function in cardiovascular disease and gastrointestinal/hepatic pathologies.

Signup for Newsletter
Scroll to Top